secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0000950170-24-060455
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences Q1 net loss $43M, cash $245.9M; advances tarcocimab and KSI-101 trials
--------------------------------------------------------------------------------

- Net loss of $43.0M ($0.82 per share) vs $70.8M ($1.35) in Q1 2023; includes $18.4M stock-based compensation.
- Cash and equivalents $245.9M; company expects runway into 2026.
- R&D expenses $29.9M, down from $56.5M YoY due to reduced tarcocimab clinical activities.
- GLOW2 Phase 3 diabetic retinopathy study actively enrolling; DAYBREAK wet AMD study activation targeted mid-2024.
- Phase 1b APEX study of KSI-101 (anti-IL-6/VEGF-trap) in macular edema expected to start enrollment in June 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017024060455/0000950170-24-060455-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017024060455/kod-20240515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-060455

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer